Objective: This study compared postoperative transfusion requirements, morbidity and mortality between adult cardiac surgery patients with preoperative anemia treated with intravenous ferric carboxymaltose and non-anemic patients.Methods: This was a prospective study including 95 patients undergoing elective open heart surgery with cardiopulmonary bypass between April 2019 and April 2022. Twenty-five (26.3%) patients had preoperative iron deficiency anemia and received intravenous ferric carboxymaltose (1000 mg, with an additional 500 mg if indicated preoperatively based on BMI). Seventy patients were non-anemic controls. Transfusion criteria were based on hemoglobin 7–8 g/dL, hemodynamic instability, or clinical judgment. Statistical analyses included Student’s t-test, Mann–Whitney U, Chi-square or Fisher’s exact tests with p 0.05). The mean operation time was shorter in the anemic treated group, partly reflecting a lower CABG rate. Baseline demographics were similar across groups (mean age 61.6 ± 11.0 vs 60.2 ± 15.9 years).Conclusion: Preoperative intravenous iron therapy in anemic patients did not reduce postoperative transfusion needs but allowed outcomes comparable to non-anemic patients. Intravenous (IV) iron therapy was safe, and patients experienced similar ICU and hospital courses. Larger randomized controlled trials are required to confirm efficacy.
Demir et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: